Long-term safety of IMG-007 for moderate-to-severe eczema
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This study checks the long-term safety and effectiveness of IMG-007 in people with moderate-to-severe atopic dermatitis (eczema) who have already finished a previous IMG-007 trial.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have moderate to severe atopic dermatitis (eczema).
- You have already completed the earlier IMG-007-203 study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called IMG-007 for adults with moderate-to-severe eczema (atopic dermatitis) that hasn't gotten better with standard creams. The goal is to see if it safely reduces itching and skin symptoms.
This study looks at the long-term safety and how well APG777 works for people with eczema (atopic dermatitis). It is for people who have already completed treatment with APG777 in an earlier study and may benefit from continuing it.
This study tests whether a new medication called ENV-294 can help adults with moderate-to-severe atopic dermatitis (eczema) that hasn't responded well to other treatments. The trial will check if the drug reduces itching and skin inflammation safely.
This trial tests an experimental drug called BBT001 for people with moderate to severe eczema (atopic dermatitis) that hasn't been helped enough by creams. The study is in early phases, so it will check how safe the drug is and how well it might work.
This trial tests a study drug (PF-08049820) for people with moderate to severe eczema who haven't found a suitable prescription treatment. It aims to see if the drug can improve skin symptoms and itching.
This trial tests a new drug called IBI3002 in people with moderate-to-severe atopic dermatitis (eczema) to see if it is safe and tolerable. It may help reduce skin inflammation and itching.
Hear when a new Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.